BioWorld

April 14, 2003

XOMA Gets More Loan Money In Raptiva Deal With Genentech

Gearing up for an approval of the psoriasis drug Raptiva by year's end, Genentech Inc. and XOMA Ltd. have retooled their agreement, with the former financing the latter's development costs $80 million at a time. (BioWorld Today) Read More

Celltech Gains Clear Advantage In Bid For Oxford GlycoSciences

Hopes Of Multiplying Monkeys To Mimic Human Disease Models Fail, Like Reproductive People Cloning

Ribozyme Regains Herzyme Control After Elan Backs Out

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 18, 2025.

An early stage 85% remissions rate in AML drives Aptevo’s stock surge

BioWorld

An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...

BIO 2025: Makary lays out FDA’s path, launches pilot review program

BioWorld

On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...

3D illustration of a chain of amino acid or biomolecules called protein

Alphadesign: AI creating proteins from scratch

BioWorld Science

The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...